David Demanse

2.4k citations

41 papers · 1.8k indexed · 2 hit papers · h-index 16

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Oncology top 5%
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research

Papers in ⓘ

Oncology 22
- Cancer Treatment and Pharmacology 12
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 5
Pulmonary and Respiratory Medicine 22
- Advanced Breast Cancer Therapies 14
- Lung Cancer Treatments and Mutations 7

Co-authors: José Baselga (15 shared papers)Jordi Rodón (15 shared papers)Howard A. Burris (9 shared papers)Malte Peters (3 shared papers)Qinhua Ru (3 shared papers)Stefan S. De Buck (3 shared papers)Michael Goldbrunner (2 shared papers)Diana C. Birle (2 shared papers)
Journals: Journal of Clinical Oncology (10 papers)Cancer Research (5 papers)Annals of Oncology (4 papers)JAMA Oncology (2 papers)Clinical Cancer Research (1 paper)
Partner nations: Switzerland United States Spain

In The Last Decade

David Demanse

40 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study 2018 · 302 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by David Demanse

Since Specialization

Citations

This map shows the geographic impact of David Demanse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Demanse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Demanse more than expected).

Fields of papers citing papers by David Demanse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Demanse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Demanse. The network helps show where David Demanse may publish in the future.

Co-authors

The 25 scholars most cited alongside David Demanse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Demanse Line = papers co-authored together David Demanse links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Johanna C. Bendell, Jordi Rodón, Howard A. Burris, Maja J.A. de Jonge, Jaap Verweij, Diana C. Birle, David Demanse, Stefan S. De Buck, Qinhua Ru, Malte Peters, Michael Goldbrunner, José Baselga Hit paper breakdown →	2011	550
2	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga Hit paper breakdown →	2018	302
3	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors Clinical Cancer Research ·Philippe L. Bédard, Josep Tabernero, Filip Jankú, Zev A. Wainberg, Luis Paz‐Ares, Johan Vansteenkiste, Eric Van Cutsem, José Manuel Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep T. Le, Kirsten Carter, David Demanse, Dénes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa	2014	257
4	Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer JAMA Oncology ·Dejan Juric, Filip Jankú, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiss‐Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo	2018	186
5	First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·H. Burris, Jordi Rodón, Shaleekha Sharma, Ronald Herbst, Josep Tabernero, J. R. Infante, Alécia Mol e Silva, David Demanse, Wolfgang Hackl, José Baselga	2010	88
6	Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. Journal of Clinical Oncology ·Ana M. González-Angulo, Dejan Juric, Guillem Argilés, Jan H.M. Schellens, Howard A. Burris, Jordan Berlin, Mark R. Middleton, Martin Schüler, Robin M.J.M. van Geel, Thorunn Helgason, Douglas Bootle, Markus Boehm, Timothy Goggin, David Demanse, Cornelia Quadt, José Baselga	2013	43
7	A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·José Baselga, Maja J. De Jonge, Jordi Rodón, H. A. Burris, Diana C. Birle, Stefan S. De Buck, David Demanse, Qinhua Ru, Michael Goldbrunner, J. C. Bendell	2010	42
8	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer Cancer Chemotherapy and Pharmacology ·Jordi Rodón, José Alejandro Pérez Fidalgo, Ian E. Krop, Howard A. Burris, Ángel Guerrero‐Zotano, Carolyn D. Britten, Carlos Becerra, Jan H.M. Schellens, Donald Richards, Martin Schüler, Maysa Abu‐Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, José Baselga	2018	40
9	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer JAMA Oncology ·Stephen J. Luen, Rebecca Asher, Chee Khoon Lee, Peter Savas, Roswitha Kammler, Patrizia Dell’Orto, Olivia Biasi, David Demanse, Lellean JeBailey, Sinead Dolan, Wolfgang Hackl, Beat Thuerlimann, Giuseppe Viale, Marco Colleoni, Meredith M. Regan, Sherene Loi	2018	32
10	A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. Journal of Clinical Oncology ·Ian E. Krop, Cristina Saura, Jordi Rodón, Carlos Becerra, Carolyn D. Britten, Steven J. Isakoff, David Demanse, Wolfgang Hackl, Cornelia Quadt, Antonio P. Silva, Howard A. Burris, Maysa Abu‐Khalaf, José Baselga	2012	28
11	Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC) Cancer Research ·Dejan Juric, Guillem Argilés, HA Burris, AM Gonzalez-Angulo, Cristina Saura, Cornelia Quadt, Mark Douglas, David Demanse, Stefan Buck, José Baselga	2012	28
12	Are waterborne astrovirus implicated in acute digestive morbidity (E.MI.R.A. study)? Journal of Clinical Virology ·Leila Gofti‐Laroche, B. Gratacap-Cavallier, David Demanse, O. Genoulaz, J. M. Seigneurin, Denis Zmirou	2003	25
13	Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial Lung Cancer ·Luis Paz‐Ares, Yasushi Goto, Wan‐Teck Lim, Balázs Halmos, Byoung Chul Cho, Manuel Cobo, J.L. González-Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bharani Dharan, Martin Reck	2024	22
14	A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. Journal of Clinical Oncology ·Philippe L. Bédard, Josep Tabernero, Razelle Kurzrock, Carolyn D. Britten, Anastasios Stathis, José Manuel Pérez-García, Angela Zubel, Ngocdiep T. Le, Kirsten Carter, Kevin M. Bellew, Chiara Gallarati, Faiz Niazi, David Demanse, Stefan S. De Buck, Cristiana Sessa	2012	20
15	Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. Journal of Clinical Oncology ·(unknown), H. A. Burris, Jordi Rodón, A.R. Abdul Razak, Maja J. De Jonge, F. Eskens, Lillian L. Siu, Qinhua Ru, Natasha F Homji, David Demanse, Emmanuelle di Tomaso, Jan Cosaert, Cornelia Quadt, José Baselga, Johanna C. Bendell	2011	19
16	Unsupervised machine-learning algorithms for the identification of clinical phenotypes in the osteoarthritis initiative database Seminars in Arthritis and Rheumatism ·David Demanse, Franziska Saxer, P Lustenberger, László B. Tankó, Philipp Nikolaus, Ilja Rasin, Damian F. Brennan, Ronenn Roubenoff, Sumehra Premji, Philip G. Conaghan, Matthias Schieker	2022	17
17	Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). Journal of Clinical Oncology ·Cristina Cruz Zambrano, Martin Schüler, Jean‐Pascal Machiels, Dagmar Hess, Luis Paz‐Ares, Ahmad Awada, Roger von Moos, Neeltje Steeghs, Jordi Rodón, Peggy De Mesmaeker, Heike Richly, Catherine Herremans, Markus Joerger, Jesús Corral Jaime, María Alsina, Fabienne Baffert, David Demanse, Vincent Duval, Alex Morozov, Luc Dirix	2014	14
18	Cross‐cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy British Journal of Urology ·Morgan Rouprêt, Vincent Hupertan, Éva Compérat, Sarah Drouin, V. Phé, Évanguelos Xylinas, David Demanse, Mathilde Sibony, François Richard, Olivier Cussenot	2009	13
19	Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study Cancer Research ·Dejan Juric, AM Gonzalez-Angulo, HA Burris, Martin Schüler, J.H.M. Schellens, Jordan Berlin, Avinash Gupta, Ruth Seggewiss‐Bernhardt, Bárbara Adamo, Marta Gil-Martín, Douglas Bootle, Markus Boehm, Stefan Buck, David Demanse, Cornelia Quadt, José Baselga	2013	12
20	Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer Cancer Research ·Filip Jankú, Dejan Juric, Javier Cortés, Hope S. Rugo, Howard A. Burris, Martin Schüler, Barbara Deschler-Baier, Mark R. Middleton, Marta Gil-Martín, Jordan Berlin, Eric P. Winer, Douglas Bootle, Lars Blumenstein, David Demanse, Christina Coughlin, Cornelia Quadt, José Baselga	2015	12

About David Demanse

David Demanse is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Hepatology and Rheumatology, having authored 41 papers that have together received 1.8k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (15 papers), Advanced Breast Cancer Therapies (14 papers), Cancer Treatment and Pharmacology (12 papers), Lung Cancer Treatments and Mutations (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Colorectal Cancer Treatments and Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). The work is most often cited by research in Genetics (363 citations), Oncology (699 citations), Cancer Research (335 citations), Pulmonary and Respiratory Medicine (630 citations) and Molecular Biology (1.2k citations). David Demanse has collaborated with scholars based in Switzerland, United States and Spain. Frequent co-authors include José Baselga, Jordi Rodón, Howard A. Burris, Malte Peters, Qinhua Ru, Stefan S. De Buck, Michael Goldbrunner, Diana C. Birle, Johanna C. Bendell and Jaap Verweij. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, JAMA Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact